



How Multidisciplinary Teams Form a Comprehensive Approach to Digitally-Derived Endpoints

Clinical Outcome Assessment Program Annual Meeting
April 16-17, 2016
Washington, D.C.

Disclaimer

The views and opinions expressed in the following slides are those of the individual presenters and should not be attributed to their respective organizations/companies, the U.S. Food and Drug Administration, or the Critical Path Institute.

These slides are the intellectual property of the individual presenters and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. All trademarks are the property of their respective owners.

Session Participants

- **Moderator**

- *Cheryl Coon, PhD* – Vice President of the Clinical Outcome Assessment (COA) Program, Critical Path Institute

- **Panelists**

- *Andrew Potter, PhD* – Associate Director, Bristol-Myers Squibb
- *Abigail Newell, PhD* – Senior Director, Research, Cancer Support Community
- *Liam Kaufman, MSc* - Executive Vice President, Cambridge Cognition
- *Marie McCarthy* – Digital Endpoint Lead Director, Novartis
- *Tim Willgoss, PhD* – Immunology Lead, Roche Products, Ltd

Session Agenda



Introduction (5 minutes)



Panel Discussion (35 minutes)



Open discussion and Q&A (20 minutes)

Panel Discussion and Q&A

- **Moderator**

- *Cheryl Coon, PhD* – Vice President of the Clinical Outcome Assessment (COA) Program, Critical Path Institute

- **Panelists**

- *Andrew Potter, PhD* – Associate Director, Bristol-Myers Squibb
- *Abigail Newell, PhD* – Senior Director, Research, Cancer Support Community
- *Liam Kaufman, MSc* – Executive Vice President, Cambridge Cognition
- *Marie McCarthy* – Digital Endpoint Lead Director, Novartis
- *Tim Willgoss, PhD* – Immunology Lead, Roche Products, Ltd



Thank You!

Advancing Drug Development. Improving Lives. Together